David Garcia, MD
Hematology · Seattle, WANPI 1649286345
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,435 of the $5,543 with a category attached, or 98.1%. Abbott accounts for 68.6% of it on its own, with 3 other manufacturers making up the rest.
Across 6 payments — averaging $923.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Janssen Scientific Affairs, LLC$2K
- AMAG Pharmaceuticals, Inc.$135
- Kala Pharmaceuticals, Inc.$108
Across 34 payments — averaging $6310.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$214K
- E.r. Squibb & Sons, L.L.C.$420
What the payments were for
- Consulting fees$5,43598%
- Food & beverage$1082%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 3 | $3,800 |
| Janssen Scientific Affairs, LLC | 1 | $1,500 |
| AMAG Pharmaceuticals, Inc. | 1 | $135 |
| Kala Pharmaceuticals, Inc. | 1 | $108 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$2,850
- XARELTO$1,500
- AMPLATZER Occluders$950
- INVELTYS$108
How this compares
$5,543 in reported general payments places this provider in the 70th percentile of 43 hematology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $11,452 |
| Enoxaparin Sodium | 11 | $6,845 |
| Tranexamic Acid | 11 | $696 |
Paid to pharmacies, not to this prescriber.
Other hematology in Seattle
- Barbara KonkleSeattle$250K
- Terry GernsheimerSeattle$148K
- Sandhya PanchSeattle$140K
- Roland WalterSeattle$92K
- Cecilia YeungSeattle$42K
- Kleber Yotsumoto FertrinSeattle$29K
- Jordan GauthierSeattle$17K
- David NgSeattle$9K
- Jose LopezSeattle$8K
- Geoffrey HillSeattle$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.